Emergent’s $261M option on vaccine contract exercised

A Gaithersburg life sciences firm that focuses on public health threats expects to receive $261 million after a federal agency exercised an option on its anthrax vaccine contract.

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *